✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Landiolol is an investigational drug.
There have been 9 clinical trials for Landiolol. The most recent clinical trial was a Phase 3 trial, which was initiated on December 13th 2019.
The most common disease conditions in clinical trials are Atrial Fibrillation, Shock, Septic, and Tachycardia. The leading clinical trial sponsors are University Hospital, Caen, AOP Orphan Pharmaceuticals AG, and Centre Hospitalier VALENCIENNES.
There are two hundred and forty-eight US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Landiolol
|Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery||Medical University of Vienna||Phase 3|
|LANdiolol MIcrocirculatory Effects During Septic chOc (MILANOS)||Assistance Publique - Hôpitaux de Paris||Phase 3|
|Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility||Centre Hospitalier Arras||N/A|
Top disease conditions for Landiolol
Top clinical trial sponsors for Landiolol
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Landiolol||See Plans and Pricing||Branched 3-phenylpropionic acid derivatives and their use||BAYER PHARMA AKTIENGESELLSCHAFT (Monheim, DE)||See Plans and Pricing|
|Landiolol||See Plans and Pricing||Substituted pyridobenzodiazepinone-derivatives and use thereof||Bayer Pharma Aktiengesellschaft (Berlin, DE)||See Plans and Pricing|
|Landiolol||See Plans and Pricing||Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use||BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)||See Plans and Pricing|
|Landiolol||See Plans and Pricing||5-aminotetrahydroquinoline-2-carboxylic acids and their use||BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)||See Plans and Pricing|
|Landiolol||See Plans and Pricing||Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro- 1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient||BAYER PHARMA AG (Berlin, DE)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Landiolol||African Regional IP Organization (ARIPO)||AP3482||2031-04-13||See Plans and Pricing|
|Landiolol||Argentina||AR085586||2031-04-13||See Plans and Pricing|
|Landiolol||Australia||AU2012242122||2031-04-13||See Plans and Pricing|
|Landiolol||Brazil||BR112013026466||2031-04-13||See Plans and Pricing|
|Landiolol||Canada||CA2832970||2031-04-13||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|